



THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1-6 (Canceled)

7. (Previously presented) A genetically manipulated, replication competent, infectious virus of the paramyxoviridae family wherein the virus genome comprises a modification wherein the modification is selected from an insertion, or deletion.

8. (Previously presented) The genetically manipulated, infectious virus of Claim 7, the genome of which has been modified to encode a heterologous sequence.

9. (Withdrawn) The virus of Claim 7 or 8 wherein the virus is a parainfluenza virus.

10. (Previously presented) The virus of Claim 7 or 8 wherein the virus is a respiratory syncytial virus.

Claim 11. Canceled

12. (Previously presented) A vaccine comprising the genetically manipulated viruses of Claims 7 or 8 and a pharmaceutically acceptable carrier.

13. (Withdrawn) A method for rescuing a genetically manipulated non-segmented negative-stranded RNA virus comprising

introducing into a host cell expressing a heterologous RNA polymerase:

- (a) one or more DNA molecules encoding the virus N, P and L proteins operably linked to a polymerase binding site;
- (b) a DNA molecule comprising the cDNA of the non-segmented negative stranded RNA virus wherein the cDNA encodes the entire genome of the virus or is modified by the incorporation of a mutation or a heterologous sequence, and wherein the cDNA is transcribed by a heterologous RNA polymerase; and

isolating the virus produced by the cell.

14. (Withdrawn) The method of Claim 13 wherein the virus is from the paramyxoviridae family.

15. (Withdrawn) The method of Claim 14 wherein the virus is parainfluenza virus.

16. (Withdrawn) The method of Claim 14 wherein the virus is a respiratory syncytial virus.

17. (Previously presented) The virus of claim 8, wherein the heterologous sequence is a non-RSV sequence.

18. (Previously presented) A genetically manipulated, replication competent, infectious non-segmented, negative strand RNA virus of the paramyxoviridae family wherein the virus genome comprises a modification wherein the modification is selected from (i) an insertion of an open reading frame encoding a viral gene product, (ii) a substitution of an

open reading frame encoding a viral gene product, or (iii) a deletion of an open reading frame encoding a viral gene product.

19. Canceled

20. (Previously presented) The virus of claim 18, wherein the virus is RSV.

21. (Previously presented) The virus of claim 18, wherein the open reading frame is the M2-2 open reading frame.

22. (Previously presented) A vaccine comprising the genetically manipulated viruses of claim 18, 20, or 21, and a pharmaceutically acceptable carrier.